世界のクッシング病市場 – 業界動向と2029年までの予測

市場分析と規模

近年、クッシング病市場は予測期間中に急速に成長すると予想されています。クッシング症候群は、高レベルのホルモンコルチゾールによって引き起こされる一連の症状です。この症候群は、高コルチゾール血症としても知られ、コルチコステロイド薬の副作用によって引き起こされることがよくあります。炎症や自己免疫疾患は、一般的にコルチコステロイドで治療されます。医原性クッシング症候群と内因性クッシング症候群は、クッシング症候群の 2 種類です。体重増加、腹部と背中の周りの脂肪組織の沈着、紫色のストレッチマーク、傷つきやすい薄い皮膚、ニキビなどの症状がよく見られます。

Data Bridge Market Research の分析によると、クッシング病市場は 2021 年に 3 億 3,380 万ドルと評価され、2029 年までに 6 億 8,689 万ドルに達し、2022 年から 2029 年の予測期間中に 9.44% の CAGR を記録すると予想されています。Data Bridge Market Research チームがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みが含まれています。

市場の定義

高血圧、赤みがかったストレッチマーク、腹部肥満、丸くて赤い顔、筋肉の衰弱、骨の弱化、肩の間の脂肪の塊、治癒が遅いデリケートな皮膚はすべて、クッシング症候群の症状と兆候です。クッシング症候群は、プレドニゾンなどのコルチゾール様薬剤の過剰投与と、コルチゾールを過剰に産生する副腎によって形成される腫瘍という 2 つの主な要因によって引き起こされます。多発性内分泌腫瘍症 1 型やカーニー複合などの遺伝性疾患に関連する腫瘍など、その他の腫瘍も、この症状の原因である可能性があります。ほとんどの場合、手術、放射線療法、化学療法を組み合わせて治療し、治癒することができます。

レポートの範囲と市場セグメンテーション

クッシング病市場の動向

ドライバー

• クッシング病の罹患率の増加

クッシング病の罹患率の上昇は、市場の成長を促進すると予測されています。Orphanet Journal of Rare Disease によると、クッシング症候群の年間発症率は人口 100 万人あたり 1 ～ 3 件と予想されていますが、2012 年の発症率は人口 100 万人あたり 40 件近くでした。クッシング症候群は、高コルチゾール血症とも呼ばれ、体内の組織が過剰な量のコルチゾールというホルモンに継続的にさらされることを特徴とするホルモン性疾患です。クッシング症候群は、20 歳から 50 歳の成人に発症します。

• 医療インフラへの投資増加

クッシング病市場の成長率に影響を与えるもう 1 つの重要な要因は、医療費の増加であり、これがインフラの改善に役立ちます。また、さまざまな政府機関が資金を増やすことで医療インフラの改善を目指しており、これが市場の動向にさらに影響を与えることになります。

• 高齢者人口の増加

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Cushing's disease, further estimated to enhance the market's growth rate. Cushing's disease is uncommon, however, it is at risk of developing in obese patients with type 2 diabetes, high blood pressure, and poorly regulated blood glucose.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Cushing's disease market. Additionally, changing lifestyles of people and rising level of disposable income will result in the expansion of Cushing's disease market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Cushing's disease market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for Cushing's disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Cushing's disease market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This Cushing's disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Cushing's disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cushing's disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cushing's Disease Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Cushing's disease market was hampered by the supply chain slowness.

Recent Development

• In March 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Isturisa (osilodrostat) oral tablets for adults suffering from Cushing's disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Isturisa is the first FDA-approved medicine to directly target cortisol overproduction by inhibiting the enzyme 11-beta-hydroxylase and stopping cortisol manufacture.

Global Cushing's Disease Market Scope

The Cushing's disease market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Surgery
• Radiation Therapy
• Drugs
  • Ketoconazole
  • Mitotane
  • Aminoglutethimide
  • Metyrapone
  • Mifepristone
  • Etomidate
  • Pasireotide
  • Others

Diagnosis

• Petrosal Sinus Sampling
• Saliva Test
• Urine and Blood Tests
• Imaging Tests
  • Computerized tomography (CT) scans
  • Magnetic resonance imaging (MRI)
  • Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cushing's Disease Market Regional Analysis/Insights

The Cushing's disease market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Cushing's disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Cushing's disease market because of the rising number of research activities and the growing prevalence of obesity population in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising awareness about the diseases will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cushing's Disease Market Share Analysis

The Cushing's disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Cushing's disease market.

Some of the major players operating in the Cushing's disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• バイエルAG（ドイツ）
• サン・ファーマシューティカル・インダストリーズ（インド）
• ブリストル・マイヤーズ スクイブ社（米国）
• イーライリリー・アンド・カンパニー（米国）
• ストライド・ファーマ・サイエンス・リミテッド（インド）
• シプラ社（米国）
• LEO Pharma A/S（デンマーク）
• オーロビンドファーマ（インド）
• ルピナス（インド）
• ヒクマ・ファーマシューティカルズPLC（英国）

SKU-54306